Triple therapy for unresectable liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three treatments for liver cancer that cannot be removed by surgery: blocking blood supply to the tumor (TACE), precise radiation (SBRT), and an immunotherapy that helps your immune system fight the cancer. It also uses a targeted medication called Donafenib. The goal is to see if this triple therapy works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your liver cancer must be confirmed by biopsy or imaging and cannot be surgically removed.
- You must not have received any prior systemic treatment (like chemotherapy, targeted therapy, or immunotherapy) for this current stage of your liver cancer.
- You must have 1 to 3 tumors, with at least one tumor larger than 5 cm.
- You should have adequate organ and blood function (e.g., good kidney and liver tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the targeted drug donafenib, immunotherapy, and local treatments (like chemo delivered directly to the liver) for people with liver cancer that cannot be removed by surgery and has stopped responding to previous treatments. The goal is to see if this new combination can shrink tumors or slow the disease.
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
This study looks at combining donafenib (a targeted therapy) with an immunotherapy drug (PD-1/L1 inhibitor) and either TACE or HAIC (two types of minimally invasive treatments for liver tumors) as a first treatment for people with liver cancer that cannot be removed by surgery. It aims to see how well this combination works and how safe it is.
This study tests a new way to treat liver cancer that can't be removed with surgery. It combines a targeted drug (donafenib) with a procedure called E-TACE, which delivers chemotherapy directly to the tumor. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of three treatments for a specific type of aggressive liver cancer called infiltrative hepatocellular carcinoma (HCC). It combines targeted therapy (lenvatinib), immunotherapy (sintilimab), and a procedure that delivers chemotherapy directly to the liver (bTAE-HAIC). The goal is to see if this triple approach works better for people with large tumors or those that have spread to the portal vein.
This study tests a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), lenvatinib (a targeted therapy pill), and tislelizumab (an immunotherapy)—for people with liver cancer that has spread into the bile ducts and can't be removed by surgery. The goal is to see if this triple therapy helps shrink or control the cancer.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.